mAbxience Achieves Milestone with European Approval for Denosumab Biosimilars mAbxience proudly announces the European Commission's approval of its denosumab biosimilars, Denbrayce® and Izamby®, enhancing access to critical therapies.

mAbxience Achieves Milestone with European Approval for Denosumab Biosimilars #Spain #Madrid #Fresenius_Kabi #Denosumab #mAbxience

mAbxience Celebrates European Commission Approval for Denosumab Biosimilars mAbxience announces that the European Commission has approved its Denosumab biosimilars, promising improved access to critical therapies across Europe.

mAbxience Celebrates European Commission Approval for Denosumab Biosimilars #Spain #Madrid #Fresenius_Kabi #Denosumab #mAbxience

Heron Therapeutics Wins Patent Case for CINVANTI® Against Fresenius Kabi USA Heron Therapeutics celebrates a crucial victory as U.S. District Court validates its CINVANTI® patents, blocking Fresenius Kabi's generic version.

Heron Therapeutics Wins Patent Case for CINVANTI® Against Fresenius Kabi USA #United_States #San_Diego #CINVANTI #Heron_Therapeutics #Fresenius_Kabi